Nonenzymatic glycation impairs the antiinflammatory properties of apolipoprotein A-I.
about
Dysfunctional High-Density Lipoprotein: An Innovative Target for Proteomics and LipidomicsHDL-apoA-I exchange: rapid detection and association with atherosclerosisApolipoprotein A-I glycation by glucose and reactive aldehydes alters phospholipid affinity but not cholesterol export from lipid-laden macrophages.Mass spectrometric immunoassay and MRM as targeted MS-based quantitative approaches in biomarker development: potential applications to cardiovascular disease and diabetesNiacin: another look at an underutilized lipid-lowering medication.A form of apolipoprotein a-I is found specifically in relapses of focal segmental glomerulosclerosis following transplantation.High density lipoprotein: it's not just about lipid transport anymoreThe association between the apolipoprotein A1/ high density lipoprotein -cholesterol and diabetes in Taiwan - a cross-sectional studySerum concentration of an inflammatory glycotoxin, methylglyoxal, is associated with increased cognitive decline in elderly individualsType I diabetes mellitus decreases in vivo macrophage-to-feces reverse cholesterol transport despite increased biliary sterol secretion in mice.HDL dysfunction in diabetes: causes and possible treatments.Novel biological functions of high-density lipoprotein cholesterolCarboxyl-Terminal Cleavage of Apolipoprotein A-I by Human Mast Cell Chymase Impairs Its Anti-Inflammatory Properties.Advanced glycation end products acutely impair ca(2+) signaling in bovine aortic endothelial cells.Glycation of apoprotein A-I is associated with coronary artery plaque progression in type 2 diabetic patients.Discoidal HDL and apoA-I-derived peptides improve glucose uptake in skeletal muscle.Different relationship between ANGPTL3 and HDL components in female non-diabetic subjects and type-2 diabetic patients.High density lipoprotein: a therapeutic target in type 2 diabetes.Dietary advanced glycation end-products aggravate non-alcoholic fatty liver disease.High density lipoproteins and endothelial functions: mechanistic insights and alterations in cardiovascular diseaseHDL and cholesterol: life after the divorce?HDL and cardiovascular disease: atherogenic and atheroprotective mechanisms.Assessing the functional properties of high-density lipoproteins: an emerging concept in cardiovascular research.Biomarkers associated with high-density lipoproteins in atherosclerotic kidney disease.Postprandial Dysmetabolism and Oxidative Stress in Type 2 Diabetes: Pathogenetic Mechanisms and Therapeutic Strategies.Mass Spectrometry-Based Proteomic Study Makes High-Density Lipoprotein a Biomarker for Atherosclerotic Vascular Disease.The anti-inflammatory function of HDL is impaired in type 2 diabetes: role of hyperglycemia, paraoxonase-1 and low grade inflammation.The causes and consequences of low levels of high density lipoproteins in patients with diabetes.Semiquantitative analysis of apolipoprotein A-I modified by advanced glycation end products in diabetes mellitus.Deleterious effect of glycation on the ability of HDL to counteract the inhibitory effect of oxidized LDL on endothelium-dependent vasorelaxation.The role and function of HDL in patients with diabetes mellitus and the related cardiovascular risk.Stimulation of phagocyte adhesion to endothelial cells by modified VLDL and HDL requires scavenger receptor BI.The apolipoprotein A-I mimetic peptide, D-4F, restrains neointimal formation through heme oxygenase-1 up-regulation.Pharmacological Intervention to Modulate HDL: What Do We Target?Glycation Reduces the Stability of ApoAI and Increases HDL Dysfunction in Diet-Controlled Type 2 Diabetes.Abnormal glucose and lipid control in non-ischemic left ventricular dysfunction.Dysfunctional HDL in diabetes mellitus and its role in the pathogenesis of cardiovascular disease.A Targeted, Differential Top-Down Proteomic Methodology for Comparison of ApoA-I Proteoforms in Individuals with High and Low HDL Efflux CapacityHigh Density Lipoprotein: Assembly, Structure, Cargo, and Functions
P2860
Q26774903-A0F0EF0E-9884-43B3-8C80-AC79ACD8CD3CQ28535779-1F793C66-AFE2-490D-8A1C-30A744BFC41FQ30431517-BDB4604C-5469-471F-8BE2-C5175FFABC08Q33643266-52572E0B-3C28-4339-B29D-8855EC272651Q34255686-DA33BDAE-A4DB-4934-A677-D7DCB011E7C0Q34498293-11E8F0B4-F37B-4BCF-8FC9-FEF837E86BCEQ34565254-0BBD5602-C70B-4930-90C0-72A996DB00D3Q35008066-644EDA3A-200E-42CC-9022-DC62E4A5CC65Q35626858-2013CF9D-5B43-4A0E-94D8-3A9196332E8CQ35747737-E5259118-40C7-4AFA-8123-F759904F8248Q35904110-64B63B52-46C0-4314-98B5-2634F7BBECA2Q36406480-6115212B-A71D-4A0E-8A8F-0F053D6B39CEQ36496865-EEAE5B59-8C53-42CB-B3CC-93144D9EEEA3Q36671087-90B99667-1817-46CD-850D-F7ADEE43B5ADQ36782743-1F79B7CF-2470-44D5-BDE1-009C66EFB507Q36842237-8956F9E1-6BEE-4A70-B928-2C6D7C913F3CQ37251396-12E05CCD-E05C-4348-B5E2-903CD3823785Q37264429-D1ACA489-90DA-48A2-959D-F6438F5BD340Q37267277-5082EFA0-0416-46D2-AB3D-FBF38D83FA08Q37305341-B6AD79D0-779C-4348-A09C-1CCEF268BC55Q37590250-57A62301-8648-4D46-B945-8EAB990FD8BCQ37838234-0E8116D2-E50F-4EE3-B74D-BCBF740C3804Q38111810-AC4ADC74-1AF6-4096-B65C-0109BC68303AQ38139862-D50ED9B0-C982-4987-80C7-665C3804CEA8Q38460480-A863C7DA-F4CF-469C-85FF-BB8CFCAAAD67Q41908048-DAE0B142-9C59-4E4B-9D01-D5039DFB2E5CQ42376634-2E469D6A-CC69-460B-8DB5-89920074A96BQ42773416-207FDA21-081D-4708-8C7F-5550798E1F39Q43714433-A52A7BFB-8053-4D4F-AF1D-C88AF145667EQ44188060-39803FF5-8D16-4E7A-B522-38EB046C80D9Q44819479-FBECF4C9-D3A7-4904-8671-85B64288FB66Q44926429-798E1FC6-F88F-4361-95AD-54F59B0A656AQ47141307-E43F9D75-3322-43DF-ACE2-931770AED2C6Q49554117-1E0BA407-A843-4454-98CC-4BACD3117AD9Q50097160-E503DB44-6833-42DF-8187-F168A07A8AACQ51334798-83736FBF-001A-4210-82B6-DF33978949EEQ53099325-693E6524-3197-4D4D-8457-6EE7E0B7CABCQ56934006-149769BF-E307-4CE4-9D94-BE8DEB04FE01Q58991979-7E996E3D-E6FA-4A71-BBF2-87FAA38D413D
P2860
Nonenzymatic glycation impairs the antiinflammatory properties of apolipoprotein A-I.
description
2010 nî lūn-bûn
@nan
2010 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Nonenzymatic glycation impairs the antiinflammatory properties of apolipoprotein A-I.
@ast
Nonenzymatic glycation impairs the antiinflammatory properties of apolipoprotein A-I.
@en
Nonenzymatic glycation impairs the antiinflammatory properties of apolipoprotein A-I.
@nl
type
label
Nonenzymatic glycation impairs the antiinflammatory properties of apolipoprotein A-I.
@ast
Nonenzymatic glycation impairs the antiinflammatory properties of apolipoprotein A-I.
@en
Nonenzymatic glycation impairs the antiinflammatory properties of apolipoprotein A-I.
@nl
prefLabel
Nonenzymatic glycation impairs the antiinflammatory properties of apolipoprotein A-I.
@ast
Nonenzymatic glycation impairs the antiinflammatory properties of apolipoprotein A-I.
@en
Nonenzymatic glycation impairs the antiinflammatory properties of apolipoprotein A-I.
@nl
P2093
P2860
P50
P1476
Nonenzymatic glycation impairs the antiinflammatory properties of apolipoprotein A-I.
@en
P2093
David J Bonnet
Estelle Nobécourt
Fatiha Tabet
Gregory J Dusting
Kerry-Anne Rye
Linda K Curtiss
Philip J Barter
Rajesh Puranik
Shisan Bao
P2860
P304
P356
10.1161/ATVBAHA.109.201715
P407
P577
2010-01-28T00:00:00Z